{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:05Z","timestamp":1787026505536,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874086, 82072797"],"award-info":[{"award-number":["81874086, 82072797"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The development and progression of glioma are associated with the tumor immune microenvironment. Diffuse low-grade gliomas (LGGs) with higher immunosuppressive microenvironment tend to have a poorer prognosis. The study aimed to find a biological marker that can reflect the tumor immune microenvironment status and predict prognosis of LGGs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The target gene tenascin-C (TNC) was obtained by screening the Chinese Glioma Genome Atlas (CGGA) and the Cancer Genome Atlas (TCGA) databases. Then samples of LGGs were collected for experimental verification with immunohistochemistry, immunofluorescence, immunoblotting, quantitative real-time PCR. ELISA was employed to determine the content of TNC in serum and examine its relationship with the tumor immune microenvironment. Eventually, the sensitivity of immunotherapy was predicted on the basis of the content of TNC in LGGs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the high-TNC subgroup, the infiltration of immunosuppressive cells was increased (MDSC: r=0.4721, Treg: r=0.3154, etc.), and immune effector cells were decreased [NKT, \u03b3\u03b4T, etc. (p&amp;lt;0.05)], immunosuppressive factors were elevated [TGF-\u03b2, IL10,\n                      <jats:italic>etc.<\/jats:italic>\n                      (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.05)], immunostimulatory factors, such as NKG2D, dropped (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.05), hypoxia scores increased (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.001), and less benefit from immunotherapy (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.05). Serum TNC level could be used to assess the status of tumor immune microenvironment in patients with grade II (AUC=0.8571; 95% CI: 0.6541-1.06) and grade III (AUC=0.8333; 95% CI: 0.6334-1.033) glioma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggested that TNC could serve as an indicator for the immunosuppressive microenvironment status and the prognosis of LGGs. Moreover, it could also act as a predictor for the effect of immunotherapy on LGG patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.824586","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T02:46:03Z","timestamp":1647398763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas"],"prefix":"10.3389","volume":"13","author":[{"given":"Po","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baofeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox234","article-title":"An NF-kappaB Signature Predicts Low-Grade Glioma Prognosis: A Precision Medicine Approach Based on Patient-Derived Stem Cells","volume":"20","author":"Ius","year":"2018","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.05.003","article-title":"A Radiosensitivity Gene Signature and PD-L1 Predict the Clinical Outcomes of Patients With Lower Grade Glioma in TCGA","volume":"128","author":"Jang","year":"2018","journal-title":"Radiother Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO Classification of Tumours of the Central Nervous System","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 Mutations in Gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12432","article-title":"WHO 2016 Classification of Gliomas","volume":"44","author":"Wesseling","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/neuonc\/nox132","article-title":"Prognostic Relevance of Genetic Alterations in Diffuse Lower-Grade Gliomas","volume":"20","author":"Aoki","year":"2018","journal-title":"Neuro Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"52","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant Gliomas in Adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas","volume":"372","author":"Brat","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","article-title":"Immune Suppression in Gliomas","volume":"151","author":"Grabowski","year":"2021","journal-title":"J Neurooncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.omto.2021.04.010","article-title":"Association of IDH Mutation and 1p19q Co-Deletion With Tumor Immune Microenvironment in Lower-Grade Glioma","volume":"21","author":"Lin","year":"2021","journal-title":"Mol Ther Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902880","article-title":"ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy","volume":"7","author":"Miao","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.10.055","article-title":"Sema3C Promotes the Survival and Tumorigenicity of Glioma Stem Cells Through Rac1 Activation","volume":"9","author":"Man","year":"2014","journal-title":"Cell Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1109","article-title":"Mechanisms Regulating the Recruitment of Macrophages Into Hypoxic Areas of Tumors and Other Ischemic Tissues","volume":"104","author":"Murdoch","year":"2004","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39506","article-title":"Hypoxia-Inducible Factor 2alpha Regulates Macrophage Function in Mouse Models of Acute and Tumor Inflammation","volume":"120","author":"Imtiyaz","year":"2010","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35213","article-title":"Stat3 Mediates Myeloid Cell-Dependent Tumor Angiogenesis in Mice","volume":"118","author":"Kujawski","year":"2008","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80005","article-title":"Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Expect the Unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of Myeloid Immune Suppressor Gr+CD11b+ Cells in Tumor-Bearing Host Directly Promotes Tumor Angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302647","article-title":"Mechanisms of Malignant Glioma Immune Resistance and Sources of Immunosuppression","volume":"10","author":"Gomez","year":"2006","journal-title":"Gene Ther Mol Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13744","article-title":"Genetic and Clinical Characterization of B7-H3 (CD276) Expression and Epigenetic Regulation in Diffuse Brain Glioma","volume":"109","author":"Wang","year":"2018","journal-title":"Cancer Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou212","article-title":"Immunotherapy Advances for Glioblastoma","volume":"16","author":"Reardon","year":"2014","journal-title":"Neuro Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02924","article-title":"Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma","volume":"9","author":"Ma","year":"2018","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-48457-6_9","article-title":"Tenascin-C Function in Glioma: Immunomodulation and Beyond","volume":"1272","author":"Yalcin","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1987","article-title":"Tenascin-C Is an Endogenous Activator of Toll-Like Receptor 4 That Is Essential for Maintaining Inflammation in Arthritic Joint Disease","volume":"15","author":"Midwood","year":"2009","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/labinvest.2017.19","article-title":"Immune Microenvironment of Gliomas","volume":"97","author":"Gieryng","year":"2017","journal-title":"Lab Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02302-5","article-title":"Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2393","article-title":"Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion","volume":"34","author":"Otvos","year":"2016","journal-title":"Stem Cells"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/4.4.278","article-title":"Epidemiology of Primary Brain Tumors: Current Concepts and Review of the Literature","volume":"4","author":"Wrensch","year":"2002","journal-title":"Neuro Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602407","article-title":"Characteristics of CD4+CD25+ Regulatory T Cells in the Peripheral Circulation of Patients With Head and Neck Cancer","volume":"92","author":"Schaefer","year":"2005","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/24.2.343","article-title":"Increase of Regulatory T Cells in the Peripheral Blood of Cancer Patients","volume":"9","author":"Wolf","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343","article-title":"How Regulatory T Cells Work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0015-7368(89)73252-7","article-title":"Immunocytochemical Study of Transforming Growth Factor Expression in Benign and Malignant Gliomas","volume":"134","author":"Samuels","year":"1989","journal-title":"Am J Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2130","article-title":"IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival","volume":"18","author":"Wainwright","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/cancers10120522","article-title":"NK Cell-Based Glioblastoma Immunotherapy","volume":"10","author":"Golan","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.1002\/cncr.11858","article-title":"MICA\/NKG2D-Mediated Immunogene Therapy of Experimental Gliomas","volume":"63","author":"Friese","year":"2003","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2540","article-title":"The Impact of O2 Availability on Human Cancer","volume":"8","author":"Bertout","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-Associated Macrophages (TAM) as Major Players of the Cancer-Related Inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J Leukoc Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3429","article-title":"Tissue Mechanics Promote IDH1-Dependent HIF1alpha-Tenascin C Feedback to Regulate Glioblastoma Aggression","volume":"18","author":"Miroshnikova","year":"2016","journal-title":"Nat Cell Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.824586\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T02:46:07Z","timestamp":1647398767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.824586\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2022.824586"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.824586","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"article-number":"824586"}}